factor pathway inhibitor appeared to be beneficial
in a study of endotoxemia in animals. These
promising studies led to major randomized, controlled
trials of the supplementation of physiologic
anticoagulants with pharmacologic doses of
activated protein C,25 antithrombin,26 and tissue
factor pathway inhibitor27 in patients with sepsis.
However, the studies showed no reductions in the
rates of death and increased bleeding episodes.
The consumption of the coagulation proteins